{"id":14387,"date":"2025-12-18T19:50:28","date_gmt":"2025-12-18T19:50:28","guid":{"rendered":"https:\/\/latamreports.com\/br\/?p=14387"},"modified":"2025-12-18T19:50:30","modified_gmt":"2025-12-18T19:50:30","slug":"stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil","status":"publish","type":"post","link":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/","title":{"rendered":"STJ mant\u00e9m fim da patente do Ozempic em 2026 e abre caminho para gen\u00e9ricos no Brasil"},"content":{"rendered":"\n<p>O Superior Tribunal de Justi\u00e7a decidiu, por unanimidade, negar o pedido da farmac\u00eautica <a href=\"https:\/\/latamreports.com\/br\/venda-de-ozempic-e-similares-passa-a-exigir-retencao-de-receita-especialistas-alertam-para-uso-abusivo\/\">Novo Nordisk <\/a>para estender a patente da <a href=\"https:\/\/latamreports.com\/br\/novo-nordisk-anuncia-corte-de-9-mil-funcionarios-em-meio-a-concorrencia-do-ozempic\/\">semaglutida<\/a>, o Ozempic, no Brasil. A decis\u00e3o mant\u00e9m o prazo original de validade, que expira em mar\u00e7o de 2026. A subst\u00e2ncia \u00e9 o princ\u00edpio ativo de medicamentos como Ozempic e Rybelsus, usados no tratamento do diabetes tipo 2 e, cada vez mais, da obesidade.<\/p>\n\n\n\n<p>O julgamento era acompanhado de perto pelo setor de sa\u00fade e pela ind\u00fastria farmac\u00eautica. Caso a prorroga\u00e7\u00e3o fosse aceita, a exclusividade poderia se estender at\u00e9 2038, o que atrasaria por mais de uma d\u00e9cada a chegada de vers\u00f5es gen\u00e9ricas ao mercado brasileiro.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Por que a decis\u00e3o do STJ \u00e9 relevante<\/h2>\n\n\n\n<p>Na pr\u00e1tica, o tribunal seguiu um entendimento j\u00e1 consolidado pelo Supremo Tribunal Federal. Desde 2021, o STF considera que n\u00e3o existe base legal para prorrogar patentes no pa\u00eds em raz\u00e3o de atrasos administrativos do Instituto Nacional da Propriedade Industrial. A legisla\u00e7\u00e3o brasileira prev\u00ea 20 anos de prote\u00e7\u00e3o, sem mecanismos autom\u00e1ticos de compensa\u00e7\u00e3o.<\/p>\n\n\n\n<p>A Novo Nordisk alegava que o exame do pedido demorou al\u00e9m do razo\u00e1vel e que esse tempo deveria ser \u201cdevolvido\u201d em forma de extens\u00e3o. O STJ, no entanto, avaliou que esse tipo de ajuste n\u00e3o est\u00e1 previsto em lei e n\u00e3o pode ser aplicado por decis\u00e3o judicial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">O que muda para pacientes e consumidores<\/h2>\n\n\n\n<p>Nada muda de forma imediata. A patente segue v\u00e1lida at\u00e9 mar\u00e7o de 2026, o que significa que, at\u00e9 l\u00e1, apenas a Novo Nordisk pode comercializar medicamentos \u00e0 base de semaglutida no pa\u00eds.<\/p>\n\n\n\n<p>Depois desse prazo, o cen\u00e1rio tende a se transformar rapidamente. Laborat\u00f3rios concorrentes j\u00e1 t\u00eam vers\u00f5es gen\u00e9ricas e similares em an\u00e1lise na Anvisa. Com mais op\u00e7\u00f5es no mercado, especialistas apontam que os pre\u00e7os podem cair em torno de 30% ou mais, a depender do n\u00edvel de concorr\u00eancia. Hoje, uma \u00fanica caneta pode custar cerca de R$ 1 mil.<\/p>\n\n\n\n<p>Atualmente, o Sistema \u00danico de Sa\u00fade n\u00e3o oferece medicamentos espec\u00edficos para o tratamento da obesidade. O custo elevado \u00e9 o principal entrave. Segundo estimativas do Minist\u00e9rio da Sa\u00fade, a incorpora\u00e7\u00e3o da semaglutida, nos valores atuais, poderia gerar um impacto anual de cerca de R$ 8 bilh\u00f5es.<\/p>\n\n\n\n<p>Com a entrada de gen\u00e9ricos mais baratos, esse cen\u00e1rio pode mudar. A pasta j\u00e1 pediu \u00e0 Anvisa prioridade na an\u00e1lise de aproximadamente 20 pedidos envolvendo semaglutida e liraglutida. A ideia \u00e9 garantir que, quando a patente cair, o mercado esteja preparado para ampliar a oferta e pressionar os pre\u00e7os para baixo.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Um problema de sa\u00fade p\u00fablica crescente<\/h3>\n\n\n\n<p>O debate ocorre em um contexto delicado. No Brasil, sete em cada dez adultos est\u00e3o acima do peso, e cerca de 31% j\u00e1 vivem com obesidade. Entre a popula\u00e7\u00e3o que depende do SUS, o avan\u00e7o \u00e9 ainda mais r\u00e1pido.<\/p>\n\n\n\n<p>Hoje, o tratamento p\u00fablico se concentra nas consequ\u00eancias da obesidade, como diabetes e hipertens\u00e3o. Medicamentos n\u00e3o fazem parte da estrat\u00e9gia. A cirurgia bari\u00e1trica \u00e9 a principal alternativa dispon\u00edvel, mas o acesso \u00e9 restrito e representa apenas uma pequena parcela dos procedimentos realizados no pa\u00eds.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Cr\u00edticas e pr\u00f3ximos passos<\/h3>\n\n\n\n<p>Representantes da ind\u00fastria farmac\u00eautica afirmam que a impossibilidade de compensar atrasos reduz o tempo efetivo de prote\u00e7\u00e3o das patentes e pode desestimular investimentos em inova\u00e7\u00e3o. Em nota, a Novo Nordisk lamentou a decis\u00e3o e defendeu mudan\u00e7as no marco legal de propriedade industrial para garantir maior previsibilidade.<\/p>\n\n\n\n<p>At\u00e9 mar\u00e7o de 2026, o mercado segue sob exclusividade. Nesse intervalo, \u00f3rg\u00e3os reguladores, o Minist\u00e9rio da Sa\u00fade e laborat\u00f3rios nacionais se organizam para um cen\u00e1rio p\u00f3s-patente que pode ampliar o acesso ao tratamento e alterar de forma significativa o mercado de medicamentos no Brasil.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>O Superior Tribunal de Justi\u00e7a decidiu, por unanimidade, negar o pedido da farmac\u00eautica Novo Nordisk para estender a patente da semaglutida, o Ozempic, no Brasil. &#8230; <a title=\"STJ mant\u00e9m fim da patente do Ozempic em 2026 e abre caminho para gen\u00e9ricos no Brasil\" class=\"read-more\" href=\"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/\" aria-label=\"Read more about STJ mant\u00e9m fim da patente do Ozempic em 2026 e abre caminho para gen\u00e9ricos no Brasil\">Read more<\/a><\/p>\n","protected":false},"author":7,"featured_media":14388,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2,13],"tags":[31],"class_list":["post-14387","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-negocios","category-politica","tag-brasil","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>STJ mant\u00e9m fim da patente do Ozempic em 2026<\/title>\n<meta name=\"description\" content=\"O STJ decidiu, por unanimidade, negar o pedido da farmac\u00eautica Novo Nordisk para estender a patente da semaglutida, o Ozempic\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"STJ mant\u00e9m fim da patente do Ozempic em 2026\" \/>\n<meta property=\"og:description\" content=\"O STJ decidiu, por unanimidade, negar o pedido da farmac\u00eautica Novo Nordisk para estender a patente da semaglutida, o Ozempic\" \/>\n<meta property=\"og:url\" content=\"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/\" \/>\n<meta property=\"og:site_name\" content=\"LatAm Reports\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/latamreports\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-18T19:50:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-18T19:50:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/latamreports.com\/br\/wp-content\/uploads\/stj-fim-patente-ozempic.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"LatAm Reports Redatores da Equipe\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@latamreports\" \/>\n<meta name=\"twitter:site\" content=\"@latamreports\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"LatAm Reports Redatores da Equipe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/\"},\"author\":{\"name\":\"LatAm Reports Redatores da Equipe\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/person\\\/a561f2de7e5ccabfab38d239b39fdb70\"},\"headline\":\"STJ mant\u00e9m fim da patente do Ozempic em 2026 e abre caminho para gen\u00e9ricos no Brasil\",\"datePublished\":\"2025-12-18T19:50:28+00:00\",\"dateModified\":\"2025-12-18T19:50:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/\"},\"wordCount\":667,\"publisher\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/stj-fim-patente-ozempic.png\",\"keywords\":[\"Brasil\"],\"articleSection\":[\"Neg\u00f3cios\",\"Pol\u00edtica\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/\",\"name\":\"STJ mant\u00e9m fim da patente do Ozempic em 2026\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/stj-fim-patente-ozempic.png\",\"datePublished\":\"2025-12-18T19:50:28+00:00\",\"dateModified\":\"2025-12-18T19:50:30+00:00\",\"description\":\"O STJ decidiu, por unanimidade, negar o pedido da farmac\u00eautica Novo Nordisk para estender a patente da semaglutida, o Ozempic\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/#primaryimage\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/stj-fim-patente-ozempic.png\",\"contentUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/stj-fim-patente-ozempic.png\",\"width\":1200,\"height\":630,\"caption\":\"STJ mant\u00e9m fim da patente do Ozempic em 2026 e abre caminho para gen\u00e9ricos no Brasil\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"STJ mant\u00e9m fim da patente do Ozempic em 2026 e abre caminho para gen\u00e9ricos no Brasil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#website\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\",\"name\":\"LatAm Reports\",\"description\":\"Not\u00edcias e opini\u00f5es de todas as Am\u00e9ricas\",\"publisher\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/latamreports.com\\\/br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\",\"name\":\"LatAm Reports\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/cropped-PNG2.png\",\"contentUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/cropped-PNG2.png\",\"width\":2522,\"height\":1014,\"caption\":\"LatAm Reports\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/latamreports\",\"https:\\\/\\\/x.com\\\/latamreports\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/person\\\/a561f2de7e5ccabfab38d239b39fdb70\",\"name\":\"LatAm Reports Redatores da Equipe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"caption\":\"LatAm Reports Redatores da Equipe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"STJ mant\u00e9m fim da patente do Ozempic em 2026","description":"O STJ decidiu, por unanimidade, negar o pedido da farmac\u00eautica Novo Nordisk para estender a patente da semaglutida, o Ozempic","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/","og_locale":"en_US","og_type":"article","og_title":"STJ mant\u00e9m fim da patente do Ozempic em 2026","og_description":"O STJ decidiu, por unanimidade, negar o pedido da farmac\u00eautica Novo Nordisk para estender a patente da semaglutida, o Ozempic","og_url":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/","og_site_name":"LatAm Reports","article_publisher":"https:\/\/facebook.com\/latamreports","article_published_time":"2025-12-18T19:50:28+00:00","article_modified_time":"2025-12-18T19:50:30+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/stj-fim-patente-ozempic.png","type":"image\/png"}],"author":"LatAm Reports Redatores da Equipe","twitter_card":"summary_large_image","twitter_creator":"@latamreports","twitter_site":"@latamreports","twitter_misc":{"Written by":"LatAm Reports Redatores da Equipe","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/#article","isPartOf":{"@id":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/"},"author":{"name":"LatAm Reports Redatores da Equipe","@id":"https:\/\/latamreports.com\/br\/#\/schema\/person\/a561f2de7e5ccabfab38d239b39fdb70"},"headline":"STJ mant\u00e9m fim da patente do Ozempic em 2026 e abre caminho para gen\u00e9ricos no Brasil","datePublished":"2025-12-18T19:50:28+00:00","dateModified":"2025-12-18T19:50:30+00:00","mainEntityOfPage":{"@id":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/"},"wordCount":667,"publisher":{"@id":"https:\/\/latamreports.com\/br\/#organization"},"image":{"@id":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/#primaryimage"},"thumbnailUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/stj-fim-patente-ozempic.png","keywords":["Brasil"],"articleSection":["Neg\u00f3cios","Pol\u00edtica"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/","url":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/","name":"STJ mant\u00e9m fim da patente do Ozempic em 2026","isPartOf":{"@id":"https:\/\/latamreports.com\/br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/#primaryimage"},"image":{"@id":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/#primaryimage"},"thumbnailUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/stj-fim-patente-ozempic.png","datePublished":"2025-12-18T19:50:28+00:00","dateModified":"2025-12-18T19:50:30+00:00","description":"O STJ decidiu, por unanimidade, negar o pedido da farmac\u00eautica Novo Nordisk para estender a patente da semaglutida, o Ozempic","breadcrumb":{"@id":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/#primaryimage","url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/stj-fim-patente-ozempic.png","contentUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/stj-fim-patente-ozempic.png","width":1200,"height":630,"caption":"STJ mant\u00e9m fim da patente do Ozempic em 2026 e abre caminho para gen\u00e9ricos no Brasil"},{"@type":"BreadcrumbList","@id":"https:\/\/latamreports.com\/br\/stj-mantem-fim-da-patente-do-ozempic-em-2026-e-abre-caminho-para-genericos-no-brasil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/latamreports.com\/br\/"},{"@type":"ListItem","position":2,"name":"STJ mant\u00e9m fim da patente do Ozempic em 2026 e abre caminho para gen\u00e9ricos no Brasil"}]},{"@type":"WebSite","@id":"https:\/\/latamreports.com\/br\/#website","url":"https:\/\/latamreports.com\/br\/","name":"LatAm Reports","description":"Not\u00edcias e opini\u00f5es de todas as Am\u00e9ricas","publisher":{"@id":"https:\/\/latamreports.com\/br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/latamreports.com\/br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/latamreports.com\/br\/#organization","name":"LatAm Reports","url":"https:\/\/latamreports.com\/br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/latamreports.com\/br\/#\/schema\/logo\/image\/","url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/cropped-PNG2.png","contentUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/cropped-PNG2.png","width":2522,"height":1014,"caption":"LatAm Reports"},"image":{"@id":"https:\/\/latamreports.com\/br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/latamreports","https:\/\/x.com\/latamreports"]},{"@type":"Person","@id":"https:\/\/latamreports.com\/br\/#\/schema\/person\/a561f2de7e5ccabfab38d239b39fdb70","name":"LatAm Reports Redatores da Equipe","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","caption":"LatAm Reports Redatores da Equipe"}}]}},"jetpack_publicize_connections":[],"_links":{"self":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/14387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/comments?post=14387"}],"version-history":[{"count":1,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/14387\/revisions"}],"predecessor-version":[{"id":14389,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/14387\/revisions\/14389"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/media\/14388"}],"wp:attachment":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/media?parent=14387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/categories?post=14387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/tags?post=14387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}